Showing 1451-1460 of 2650 results for "".
- Biosimilar Update: Fresenius Kabi’s Idacio Joins Growing List of Available Humira Biosimilarshttps://practicaldermatology.com/news/biosimilar-update-fresenius-kabis-idacio-joins-growing-list-of-available-humira-biosimilars/2461836/Fresenius Kabi’s citrate-free adalimumab biosimilar
- Aveeno Names Winners of the 2022 Skin Health Accelerator Startup Pitch Competitionhttps://practicaldermatology.com/news/aveeno-names-winners-of-the-2022-skin-health-accelerator-startup-pitch-competition/2461263/Aveeno awarded the winners of the second installment of the brand’s
- Data Demonstrate Safety, Efficacy of Dupilumab for AD in Patients as Young as Six Monthshttps://practicaldermatology.com/news/data-demonstrate-safety-efficacy-of-dupilumab-for-ad-in-patients-as-young-as-six-months/2461005/Data demonstrating the safety and efficacy of Sanofi and Regeneron’s
- DefenAge's D2-Minute Reveal Masque Named NewBeauty's 2019 Best Brightening Maskhttps://practicaldermatology.com/news/defenages-d2-minute-reveal-masque-named-newbeautys-2019-best-brightening-mask/2459973/DefenAge’s D2-Minute Reveal Masque is the
- Alastin Skincare's INhance Post-Injection Serum Reduces Bruisinghttps://practicaldermatology.com/news/alastin-skincares-inhance-post-injection-serum-reduces-bruising/2460419/Alastin’s Skincare’s INhance Post-Injection Serum with TriHex Technology can help reduce post-injection bruising and swelling, according to a report inthe Journal of Drugs in Dermatology. In
- HydraFacial Company Partners With Alastin Skincarehttps://practicaldermatology.com/news/hydrafacial-company-partners-with-alastin-skincare/2459931/Alastin Skincare’s TriHex-Pro Skin Booster Serum is now available at HydraFacial providers across the United States. The key ingredient in the TriHex-Pro Skin Booster Serum is Alastin's proprieta
- FDA Advisory Arm Backs XELJANZ for PsAhttps://practicaldermatology.com/news/fda-advisory-arm-backs-xeljanz-for-psa/2458098/The United States Food and Drug Administration’s (FDA) Arthritis Advisory Committee recommends the approval of Pfizer's XELJANZ® (tofacitinib) for the treatment of adults with active psoriatic arthritis (PsA). The Arthritis Advisory Commit
- Do the FDA's Proposed Regulations on Tanning Bed Use Go Far Enough?https://practicaldermatology.com/news/do-the-fdas-proposed-regulations-on-tanning-bed-use-go-far-enough/2458646/As the comment period on the US Food and Drug Administration’s proposal to restrict tanning bed use winds down, researchers are weighing in on the proposal's merits and potential shortfalls. Investigators
- Almirall and University of Michigan Collaborate to Gain Understanding of Disease Drivers in Hidradenitis Suppurativahttps://practicaldermatology.com/news/almirall-and-university-of-michigan-collaborate-to-gain-understanding-of-disease-drivers-in-hidradenitis-suppurativa/2461107/Almirall, S.A. entered into a collaboration agreement with the University of Michigan to accelerate the understanding of the factors that trigger hidradenitis suppurativa. Through this partnership, Almirall's expertise in skin diseases will be combined with the knowledge of the Dermatolo
- GHG Audit Shows Key Emission Sources in Dermatology Practicehttps://practicaldermatology.com/news/ghg-audit-shows-key-emission-sources-dermatology-practice/2470894/A new study has identified scope 3 emissions, particularly purchased goods and services, as the largest contributor to the carbon footprint of an outpatient dermatology clinic, accounting for 51.1% of total greenhouse gas (GHG) emissions. The research, conducted at a University of Pennsylv